{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:45:46Z","timestamp":1773089146481,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106305","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:56:57Z","timestamp":1739001417000},"page":"106305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study"],"prefix":"10.1016","volume":"95","author":[{"given":"Xavier","family":"Moisset","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-5464","authenticated-orcid":false,"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriane","family":"Deygas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Civet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Bourel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Larrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106305_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101396","article-title":"Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims","volume":"36","author":"Bruno","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106305_bib0002","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.neurol.2022.02.461","article-title":"Rationale for off-label treatments use in primary progressive multiple sclerosis: a review of the literature","volume":"178","author":"Chedid","year":"2022","journal-title":"Rev. Neurol. (Paris)"},{"issue":"4","key":"10.1016\/j.msard.2025.106305_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: a multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106305_bib0004","unstructured":"EMA. OCREVUS\u2122 summary of product characteristics 2022. [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf."},{"issue":"6","key":"10.1016\/j.msard.2025.106305_bib0005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.neurol.2014.02.007","article-title":"Co\u00fbts de la scl\u00e9rose en plaques en France","volume":"170","author":"Fromont","year":"2014","journal-title":"Rev. Neurol. (Paris)"},{"issue":"2","key":"10.1016\/j.msard.2025.106305_bib0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol. Ther."},{"issue":"16","key":"10.1016\/j.msard.2025.106305_bib0007","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"2 Suppl","key":"10.1016\/j.msard.2025.106305_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1352458512441566a","article-title":"Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France","volume":"18","author":"Johansson","year":"2012","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106305_bib0009","first-page":"e11","article-title":"Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada","volume":"19","author":"Karampampa","year":"2012","journal-title":"J. Populat. Therapeut. Clin. Pharmacol. = Journal de la therapeutique des populations et de la pharmacologie clinique"},{"issue":"5","key":"10.1016\/j.msard.2025.106305_bib0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14737175.2022.2061950","article-title":"Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France","volume":"22","author":"Leblanc","year":"2022","journal-title":"Expert. Rev. Neurother."},{"issue":"2_suppl","key":"10.1016\/j.msard.2025.106305_bib0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1352458517708125","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for France","volume":"23","author":"Lebrun-Frenay","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106305_bib0012","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.neurol.2016.01.203","article-title":"Co\u00fbt de la scl\u00e9rose en plaques en France : description des diff\u00e9rents postes de d\u00e9penses \u00e0 partir des bases de donn\u00e9es de l'assurance maladie","volume":"172","author":"Lefeuvre","year":"2016","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2025.106305_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104109","article-title":"Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: final results from the PRO-MSACTIVE study","volume":"68","author":"Manchon","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106305_bib0014","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1007\/s00415-022-11320-7","article-title":"Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy","volume":"269","author":"Moccia","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106305_bib0015","series-title":"Atlas of MS 2020 \u2013Epidemiology report","year":"2020"},{"key":"10.1016\/j.msard.2025.106305_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102162","article-title":"A literature review of cost-of-illness studies on the economic burden of multiple sclerosis","volume":"43","author":"Paz-Zulueta","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106305_bib0017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neurol.2023.12.007","article-title":"Prevalence of multiple sclerosis in France in 2021: data from the French health insurance database","volume":"180","author":"Pierret","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"issue":"2","key":"10.1016\/j.msard.2025.106305_bib0018","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/ene.15142","article-title":"Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study","volume":"29","author":"Pontieri","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106305_bib0019","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1472-6963-13-131","article-title":"Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity","volume":"13","author":"Raimundo","year":"2013","journal-title":"BMC Health Serv. Res."},{"issue":"12","key":"10.1016\/j.msard.2025.106305_bib0020","first-page":"1354","article-title":"Economic burden of multiple sclerosis in the United States: a systematic literature review","volume":"29","author":"Schauf","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"4","key":"10.1016\/j.msard.2025.106305_bib0021","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev. Epidemiol. Sante Publique"},{"issue":"5","key":"10.1016\/j.msard.2025.106305_bib0022","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14737167.2021.1945926","article-title":"Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database","volume":"21","author":"Vandhuick","year":"2021","journal-title":"Expert Rev. Pharmacoecon. Outcome. Res."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:41Z","timestamp":1741841321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"alternative-id":["S2211034825000495"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106305","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106305"}}